Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

Approximately 15% of acral and mucous melanomas carry activating mutations in oncogene. There is a diversity of spectrum of mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patient with р...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in oncology 2019-01, Vol.12 (1), p.109-112
Hauptverfasser: Orlova, Kristina V, Yanus, Grigory A, Aleksakhina, Svetlana N, Venina, Aigul R, Iyevleva, Aglaya G, Demidov, Lev V, Imyanitov, Evgeny N
Format: Artikel
Sprache:eng
Schlagworte:
Case Report
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Approximately 15% of acral and mucous melanomas carry activating mutations in oncogene. There is a diversity of spectrum of mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patient with р.T632I mutation, who failed to respond to imatinib.
ISSN:1662-6575
1662-6575
DOI:10.1159/000495782